Clinical trials: Pancreas Adenocarcinoma
Pancreatic Cancer
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
PURPOSE: This phase II trial is studying how well gemcitabine and erlotinib work when given before and after surgery in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT00733746
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Adenocarcinoma
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer.
- Trial name
- NCT00327327
- Testing
- imexon, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 105 people
- Sponsor
- AmpliMed Corporation
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Esophageal Adenocarcinoma, Gastric Cancer
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment.
- Conditions
- Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CIT-SEQ (NCT07660627)
- Testing
- NGS sequencing of mutations selected based on sequencing of primary tumors
- Where
- Czechia
- Volunteers
- 34 people
- Sponsor
- Masaryk Memorial Cancer Institute
Pancreatic Cancer
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied.
- Trial name
- NCT02241187
- Testing
- PEGPH20, Cetuximab, DW & DCE-MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, Adenocarcinoma of Lung
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Background: Malignant mesothelioma is a form of cancer that develops on the protective lining that covers the body's internal organs. It most often occurs on the lining of the lungs and chest wall or the lining of the abdomen.
- Conditions
- Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms
- Trial name
- NCT01362790
- Testing
- Pentostatin, Cyclophosphamide, SS1(dsFv)PE38 - lot 073I0809
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Adenocarcinoma, Pancreatic Cancer Metastatic
Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer
Adenocarcinoma of the pancreas is a major public health issue because of its disastrous prognosis. The symptomatology of locally advanced or metastatic forms, particularly painful, is often major and difficult to balance…
- Conditions
- Adenocarcinoma, Pancreatic Cancer Metastatic, Pain
- Trial name
- PANTELO (NCT04667403)
- Testing
- Telemedicine
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Cancerologie de l'Ouest
Pancreatic Adenocarcinoma, Chronic Pancreatitis
Endoscopic Ultrasound Elastography in Pancreatic Masses
The aim of the study is to assess elastography during EUS examinations of focal pancreatic masses, and to consequently differentiate benign versus malignant pancreatic masses in a prospective multi-center design.
- Trial name
- EUS-EG (NCT00909103)
- Where
- 18 sites in Belgium, Denmark and 8 more
- Volunteers
- 285 people
- Sponsor
- University of Medicine and Pharmacy Craiova
Advanced Cancer, Pancreatic Cancer
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Determine Phase 2 dose of study drug
- Conditions
- Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer
- Trial name
- NivoPlus (NCT02423954)
- Testing
- Temsirolimus, Irinotecan, Irinotecan + capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Western Regional Medical Center
Metastatic Pancreatic Adenocarcinoma
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.
- Trial name
- NCT02985125
- Testing
- LEE011, Everolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Georgetown University
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Pancreatic Adenocarcinoma, Weight Loss
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status.
- Trial name
- SIBO in PDAC (NCT06988150)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers.
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06428409
- Testing
- Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
This study is to determine the efficacy of bevacizumab and gemcitabine in combination with radiation therapy in the preoperative treatment of potentially-resectable subjects with pancreatic cancer.
- Trial name
- NCT00557492
- Testing
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amer Zureikat
Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
This study looks at better ways to measure how tumors respond to treatment before surgery. Today, doctors often use RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), which measures the longest diameter across a tumor on…
- Conditions
- Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
- Trial name
- NCT07319767
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.
- Trial name
- NCT07303465
- Testing
- RNK08954
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.